These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 8648761)

  • 61. Growth characteristics of ChimeriVax-DEN2 vaccine virus in Aedes aegypti and Aedes albopictus mosquitoes.
    Johnson BW; Chambers TV; Crabtree MB; Bhatt TR; Guirakhoo F; Monath TP; Miller BR
    Am J Trop Med Hyg; 2002 Sep; 67(3):260-5. PubMed ID: 12408664
    [TBL] [Abstract][Full Text] [Related]  

  • 62. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
    Durbin AP; McArthur JH; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
    Hum Vaccin; 2006; 2(6):255-60. PubMed ID: 17106267
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Chimeric flaviviruses: novel vaccines against dengue fever, tick-borne encephalitis, and Japanese encephalitis.
    Lai CJ; Monath TP
    Adv Virus Res; 2003; 61():469-509. PubMed ID: 14714441
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Wild dengue virus types 1, 2 and 3 viremia in rhesus monkeys.
    Freire M; Marchevsky R; Almeida L; Yamamura A; Caride E; Brindeiro P; Motta M; Nogueira R; Kubelka C; Bonaldo M; Galler R
    Mem Inst Oswaldo Cruz; 2007 May; 102(2):203-8. PubMed ID: 17426886
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Tetravalent recombinant dengue virus-like particles as potential vaccine candidates: immunological properties.
    Liu Y; Zhou J; Yu Z; Fang D; Fu C; Zhu X; He Z; Yan H; Jiang L
    BMC Microbiol; 2014 Dec; 14():233. PubMed ID: 25520151
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Structural and biophysical analysis of sero-specific immune responses using epitope grafted Dengue ED3 mutants.
    Kulkarni MR; Islam MM; Numoto N; Elahi M; Mahib MR; Ito N; Kuroda Y
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt A):1438-43. PubMed ID: 26160751
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.
    McBurney SP; Sunshine JE; Gabriel S; Huynh JP; Sutton WF; Fuller DH; Haigwood NL; Messer WB
    Vaccine; 2016 Jun; 34(30):3500-7. PubMed ID: 27085173
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Infectivity of West Nile/dengue chimeric viruses for West Nile and dengue mosquito vectors.
    Hanley KA; Goddard LB; Gilmore LE; Scott TW; Speicher J; Murphy BR; Pletnev AG
    Vector Borne Zoonotic Dis; 2005; 5(1):1-10. PubMed ID: 15815144
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mapping the Human Memory B Cell and Serum Neutralizing Antibody Responses to Dengue Virus Serotype 4 Infection and Vaccination.
    Nivarthi UK; Kose N; Sapparapu G; Widman D; Gallichotte E; Pfaff JM; Doranz BJ; Weiskopf D; Sette A; Durbin AP; Whitehead SS; Baric R; Crowe JE; de Silva AM
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28031369
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys.
    Monath TP; Levenbook I; Soike K; Zhang ZX; Ratterree M; Draper K; Barrett AD; Nichols R; Weltzin R; Arroyo J; Guirakhoo F
    J Virol; 2000 Feb; 74(4):1742-51. PubMed ID: 10644345
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Pediatric measles vaccine expressing a dengue tetravalent antigen elicits neutralizing antibodies against all four dengue viruses.
    Brandler S; Ruffie C; Najburg V; Frenkiel MP; Bedouelle H; Desprès P; Tangy F
    Vaccine; 2010 Sep; 28(41):6730-9. PubMed ID: 20688034
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.
    Blaney JE; Sathe NS; Goddard L; Hanson CT; Romero TA; Hanley KA; Murphy BR; Whitehead SS
    Vaccine; 2008 Feb; 26(6):817-28. PubMed ID: 18191005
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Improvement of the Dengue Virus (DENV) Nonhuman Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against DENV-2 and -4.
    Barban V; Mantel N; De Montfort A; Pagnon A; Pradezynski F; Lang J; Boudet F
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593041
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Vaccine candidates derived from a novel infectious cDNA clone of an American genotype dengue virus type 2.
    Blaney JE; Hanson CT; Hanley KA; Murphy BR; Whitehead SS
    BMC Infect Dis; 2004 Oct; 4():39. PubMed ID: 15461822
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Vaccination of rhesus macaques against dengue-2 virus with a plasmid DNA vaccine encoding the viral pre-membrane and envelope genes.
    Putnak R; Fuller J; VanderZanden L; Innis BL; Vaughn DW
    Am J Trop Med Hyg; 2003 Apr; 68(4):469-76. PubMed ID: 12875299
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Persistence of neutralizing antibody and its protective efficacy induced by a live attenuated tetravalent dengue vaccine, KD-382, in cynomolgus monkeys.
    Yoshimura M; Shinmura Y; Shishido T; Takagi S; Kameyama K; Sonoda K; Yoksan S; Kimachi K
    Vaccine; 2021 May; 39(23):3169-3178. PubMed ID: 33941407
    [TBL] [Abstract][Full Text] [Related]  

  • 77. An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity.
    Khanam S; Pilankatta R; Khanna N; Swaminathan S
    Vaccine; 2009 Oct; 27(43):6011-21. PubMed ID: 19665609
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers.
    Durbin AP; McArthur J; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
    Hum Vaccin; 2006; 2(4):167-73. PubMed ID: 17012875
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Carboxy-terminally truncated Dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to Dengue 4 virus challenge in mice.
    Muné M; Rodríguez R; Ramírez R; Soto Y; Sierra B; Rodríguez Roche R; Marquez G; Garcia J; Guillén G; Guzmán MG
    Arch Virol; 2003 Nov; 148(11):2267-73. PubMed ID: 14579183
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Mutations which enhance the replication of dengue virus type 4 and an antigenic chimeric dengue virus type 2/4 vaccine candidate in Vero cells.
    Blaney JE; Manipon GG; Firestone CY; Johnson DH; Hanson CT; Murphy BR; Whitehead SS
    Vaccine; 2003 Oct; 21(27-30):4317-27. PubMed ID: 14505914
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.